AbCellera’s ABCL635 cut hot flashes by 83%. Can the biotech turn Phase 2 success into a viable drug?
AbCellera heads to UBS after positive ABCL635 Phase 2 results and a $200 million financing. Examine its clinical and commercial priorities.
Pharma & Biotech